Page 131 - 2019_10 resto del Mondo_web

AXL and resistance to quizartinib in the hematopoietic niche
121(11):2064-2073.
23. Park IK, Mundy-Bosse B, Whitman SP, et al.
Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-target- ed therapy in acute myeloid leukemia. Leukemia. 2015;29(12):2382-2389.
24. Rankin EB, Fuh KC, Castellini L, et al. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. Proc Natl Acad Sci U S A. 2014;111(37):13373-13378.
25. Porteu F, Rouyez MC, Cocault L, et al. Functional regions of the mouse throm- bopoietin receptor cytoplasmic domain: evidence for a critical region which is involved in differentiation and can be com- plemented by erythropoietin. Mol Cell Biol. 1996;16(5):2473-2482.
26. Wingelhofer B, Maurer B, Heyes EC, et al. Pharmacologic inhibition of STAT5 in acute myeloid leukemia. Leukemia. 2018;32(5): 1135-1146.
27. Casetti L, Martin-Lanneree S, Najjar I, et al. Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells. Cancer Res. 2013;73(7):2052-2058.
28. Holland SJ, Pan A, Franci C, et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast can- cer. Cancer Res. 2010;70(4):1544-1554.
29. Angelini DF, Ottone T, Guerrera G, et al. A Leukemia-Associated CD34/CD123/ CD25/CD99+ immunophenotype identi- fies FLT3-mutated clones in acute myeloid leukemia. Clin Cancer Res. 2015;21(17): 3977-3985.
30. Rauch PJ, Ellegast JM, Widmer CC, et al. MPL expression on AML blasts predicts peripheral blood neutropenia and thrombo- cytopenia. Blood. 2016;128(18):2253-2257.
31. Mishra A, Wang J, Shiozawa Y, et al. Hypoxia Stabilizes GAS6/Axl Signaling in Metastatic Prostate Cancer. Mol Can Res. 2012;10(6):703-712.
32. Braun M, Qorraj M, Buttner M, et al. CXCL12 promotes glycolytic reprogram- ming in acute myeloid leukemia cells via the CXCR4/mTOR axis. Leukemia. 2016;30(8):1788-1792.
33. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006;12(10):1167-1174.
unique marker for human acute myeloge- nous leukemia stem cells. Leukemia. 2000;14(10):1777-1784.
42. Riccioni R, Diverio D, Riti V, et al. Interleukin (IL)-3/granulocyte macrophage- colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor. Br J Haematol. 2009;144(3):376-
34. Dias S, Hattori K, Zhu Z, et al. Autocrine
stimulation of VEGFR-2 activates human 387.
leukemic cell growth and migration. J Clin
Invest. 2000;106(4):511-521.
35. Schliemann C, Bieker R, Padro T, et al.
Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia. Haematologica. 2006;91(9):1203-1211.
36. Brenner AK, Nepstad I, Bruserud O. Mesenchymal Stem Cells Support Survival and Proliferation of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular Mechanisms. Front Immunol. 2017;8:106.
37. Traer E, Martinez J, Javidi-Sharifi N, et al. FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. Cancer Res. 2016;76(22):6471-6482.
38. Abdul-Aziz AM, Shafat MS, Sun Y, et al. HIF1alpha drives chemokine factor pro- tumoral signaling pathways in acute myeloid leukemia. Oncogene. 2018;37(20): 2676-2686.
39. Ellegast JM, Rauch PJ, Kovtonyuk LV, et al. inv(16) and NPM1mut AMLs engraft human cytokine knock-in mice. Blood. 2016;128(17):2130-2134.
40. Vergez F, Green AS, Tamburini J, et al. High levels of CD34+/CD38low/CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest- Est des Leucémies Aiguës et Maladies du Sang (GOELAMS) study. Haematologica. 2011;96(12):1792-1798.
41. Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a
43. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell. 2007;131(6):1124-1136.
44. Fatrai S, Wierenga AT, Daenen SM, Vellenga E, Schuringa JJ. Identification of HIF2alpha as an important STAT5 target gene in human hematopoietic stem cells. Blood. 2011;117(12):3320-3330.
45. Ruan G-X, Kazlauskas A. Axl is essential for VEGF-A-dependent activation of PI3K/Akt. EMBO J. 2012;31(7):1692-1703.
46. Gioia R, Tregoat C, Dumas PY, et al. CBL controls a tyrosine kinase network involv- ing AXL, SYK and LYN in nilotinib-resistant chronic myeloid leukaemia. J Pathol. 2015; 237(1):14-24.
47. Spencer JA, Ferraro F, Roussakis E, et al. Direct measurement of local oxygen con- centration in the bone marrow of live ani- mals. Nature. 2014;508(7495):269-273.
48. Sironi S, Wagner M, Kuett A, et al. Microenvironmental hypoxia regulates FLT3 expression and biology in AML. Sci Rep. 2015;5:17550.
49. Jin L, Tabe Y, Lu H, et al. Mechanisms of apoptosis induction by simultaneous inhi- bition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenviron- ment. Cancer Lett. 2013;329(1):45-58.
50. Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017; 18(8):1061-1075.
haematologica | 2019; 104(10)
2027